Pharmaceuticals News and Research

RSS

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb Company and AstraZeneca announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb.

10 Aug 2012

BMJ authors challenge pharma's concerns about 'innovation crisis'

For the past decade or so, we've been hearing repeatedly about an "innovation" crisis in pharmaceuticals. Big Pharma and its friends in government and elsewhere have claimed that research into new drugs is slowing down, primarily, they say, because of onerous regulatory demands

10 Aug 2012

FDA approves Mylan's ANDA for generic Provigil

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP,100 mg and 200 mg.

10 Aug 2012

IRIN examines administration of methadone as treatment for people who inject drugs in Bangladesh

"Methadone treatment is proving to be the most efficient way to wean people in Bangladesh from addiction to buprenorphine, a pharmaceutical drug, and health experts say it should be expanded to reach thousands more drug users to prevent the spread of HIV," IRIN reports.

10 Aug 2012

Two-drug combination helps combat cocaine addiction

A combination of two existing pharmaceutical drugs may soon be used to treat cocaine addiction, findings from an animal study in Science Translational Medicine suggest.

10 Aug 2012

Syrians in urgent need of life-saving medicines as fighting escalates, WHO warns

"Syrians are in urgent need of life-saving medicines following an escalation in fighting, which also threatens further food shortages, U.N. agencies warned on Tuesday," Agence France-Presse reports.

9 Aug 2012

Researchers uncover new key player in amplifying stress in early stages of diabetes

At its most fundamental level, diabetes is a disease characterized by stress—microscopic stress that causes inflammation and the loss of insulin production in the pancreas, and system-wide stress due to the loss of that blood-sugar-regulating hormone.

9 Aug 2012

Mindfulness yoga may offer effective treatment for depressed new mothers

It's no secret that pregnancy hormones can dampen moods, but for some expectant moms, it's much worse: 1 in 5 experience major depression. Now, new research shows that an age-old recommended stress-buster may actually work for this group of women: yoga.

9 Aug 2012

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

A fine-tuned combination of two existing pharmaceutical drugs has shown promise as a potential new therapy for people addicted to cocaine—a therapy that would reduce their craving for the drug and blunt their symptoms of withdrawal.

9 Aug 2012

Provista, Physician Strategy Group at USPI partner to deliver supply chain services

United Surgical Partners International's (USPI) Physician Strategy Group (PSG) and Provista, LLC announced today that they are working together to deliver supply chain services to over 9,000 physician customers who perform procedures at surgical facilities centers operated by USPI. The program, called Purchasing Plus, is expected to help those physicians save 10-15% on supplies, services, and capital equipment.

9 Aug 2012

Advocacy groups warn Trans-Pacific Partnership could affect access to low-cost medications, Bloomberg reports

Bloomberg Businessweek examines how ongoing trade negotiations related to the Trans-Pacific Partnership could affect access to quality low-cost medications, including antiretrovirals, in low- and middle-income countries. "Protecting the patents of drug makers ... as part of the Trans-Pacific Partnership has drawn criticism from groups such as Doctors Without Borders and Public Citizen," and "the proposed accord has also spurred calls from U.S. lawmakers for greater transparency about the negotiations," the news service writes.

9 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

9 Aug 2012

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).

9 Aug 2012

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they have received $1.5 million in funding to commercialize a technology for Parkinson’s disease (PD) patients that will better assess motor symptoms in response to new deep brain stimulation (DBS) and pharmaceutical therapies.

8 Aug 2012

Bristol-Myers Squibb completes tender offer for all outstanding shares of Amylin

Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc. at a purchase price of $31.00 per share.

8 Aug 2012

Pharmaceuticals News and Research

Bristol-Myers Squibb completes acquisition of Amylin

BMJ authors challenge pharma's concerns about 'innovation crisis'

FDA approves Mylan's ANDA for generic Provigil

IRIN examines administration of methadone as treatment for people who inject drugs in Bangladesh

Two-drug combination helps combat cocaine addiction

Syrians in urgent need of life-saving medicines as fighting escalates, WHO warns

Researchers uncover new key player in amplifying stress in early stages of diabetes

Mindfulness yoga may offer effective treatment for depressed new mothers

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

Provista, Physician Strategy Group at USPI partner to deliver supply chain services

Advocacy groups warn Trans-Pacific Partnership could affect access to low-cost medications, Bloomberg reports

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Bristol-Myers Squibb completes tender offer for all outstanding shares of Amylin

First Edition: August 8, 2012

APCER Pharma updates and enhances its website

Columbia Laboratories second quarter total net revenues decrease to $8.2 million

Global market value of Alzheimer's disease therapeutics could soar to $8 billion: GEN

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence